British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update

Smith, Catherine; Yiu, Zenas Z N; Bale, Tracy; Burden, A. David; Coates, Laura C.; Edwards, W.; MacMahon, Eithne; Mahil, Satveer K; McGuire, Arlene; Murphy, Ruth; Nelson‐Piercy, Catherine; Owen, Caroline M.; Parslew, Richard; Uthman, Olalekan A.; Woolf, Richard; Manounah, L; Ezejimofor, Martinsixtus C.; Exton, L.S.; Mustapa, M.F. Mohd

doi:10.1111/bjd.19039

Cited by 138 publications

(162 citation statements)

References 4 publications

Supporting

Mentioning

153

Contrasting

Unclassified

Order By: Relevance

“…6 And the nationwide prevalence of LTBI in Italian patients with chronic plaque psoriasis was 8.3%. 7 It is suggested that all psoriasis patients who are about to receive biologic therapy should be screened for TB [8][9][10] and closely monitored for active TB infection in the process. 11 The first generation of biologics target TNF-α and carry a certain risk of reactivation of opportunistic infections, cancer, LTBI, or hepatitis B virus (HBV) infection.…”

Section: Introductionmentioning

confidence: 99%

Is chemoprophylaxis necessary for all latent tuberculosis infection patients receivingIL‐17 inhibitors? A cohort study

Shen

Zhang

Zhou

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

The tuberculosis (TB) burden is high in China, with a 32% prevalence of latent tuberculosis infection (LTBI) in Beijing. Screening for LTBI and the chemoprophylaxis of positive patients are recommended prior to biologic therapy. To evaluate the TBrelated safety of secukinumab (SEC) in a cohort of plaque psoriasis patients with LTBI receiving different treatments. Plaque psoriasis patients eligible for SEC treatment were screened for TB. LTBI patients (QuantiFeron-TB test positive, QFT+) receiving SEC were closely monitored by chest radiograph, ESR or hs-CRP, and blood counts every 12 to 20 weeks for active TB infection. QFT_patients receiving SEC treatment were screened for LTBI every 6 to 12 months. Of 42 patients treated with SEC, 19 were QFT+ (45.24%). A QFT_patient became QFT+ after 6 months treatment. Two patients started SEC treatment from 2015 to 2016 and were followed up 268 and 216 weeks later, respectively. Three patients received chemoprophylaxis, 17 did not because of safety concerns or being unable to complete the process. During the 16-to 268-week follow-up, no signs of TB reactivation were observed in the 20 LTBI patients receiving SEC. Plaque psoriasis patients with LTBI who received no chemoprophylaxis could be safely treated with SEC.

show abstract

Section: Introductionmentioning

confidence: 99%

Is chemoprophylaxis necessary for all latent tuberculosis infection patients receivingIL‐17 inhibitors? A cohort study

Shen

Zhang

Zhou

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…In the USA [ 2 ], the UK [ 30 ] and Japan [ 31 ], currently available biological agents for the treatment of plaque psoriasis include the TNF-α inhibitors infliximab, adalimumab, etanercept (US and UK only) and certolizumab pegol (US and UK only); the IL-12/23 inhibitor ustekinumab; the IL-17 inhibitors secukinumab, ixekizumab and brodalumab; and the IL-23 inhibitors guselkumab, tildrakizumab (US and UK only) and risankizumab [ 2 , 31 ]. European S3 guidelines published prior to the EU approval of risankizumab strongly recommend adalimumab, etanercept, infliximab, ustekinumab and secukinumab for the second-line treatment of plaque psoriasis [ 3 ].…”

Section: Place Of Risankizumab In the Management Of Moderate To Severmentioning

confidence: 99%

“…efficacy and safety) and patient-related factors (e.g. disease severity, comorbidities, personal preferences), as well as drug-related factors such as the route and frequency of administration [ 2 , 30 , 31 ]. All of the newer biological agents approved for plaque psoriasis are administered via subcutaneous injection.…”

Section: Place Of Risankizumab In the Management Of Moderate To Severmentioning

confidence: 99%

Risankizumab: A Review in Moderate to Severe Plaque Psoriasis

Blair

2020

Drugs

View full text Add to dashboard Cite

Risankizumab (Skyrizi ® ; risankizumab-rzaa) is a humanized immunoglobulin (Ig) G1 monoclonal antibody that specifically targets the p19 subunit of interleukin (IL)-23, thereby inhibiting IL-23-dependent cell signaling. Subcutaneous risankizumab is approved for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy (in the EU), those who are candidates for systemic therapy or phototherapy (in the USA) and those who have an inadequate response to conventional therapies (in Japan). In pivotal phase III trials (UltIMMa-1, UltIMMa-2, IMMvent and IMMhance), risankizumab was more effective than placebo, ustekinumab and adalimumab with regard to the proportion of patients achieving ≥ 90% improvement from baseline in Psoriasis Area and Severity Index score (PASI 90) and a static Physician’s Global Assessment score of 0 or 1 at week 16, with these benefits maintained over the longer term. In supportive head-to-head trials, risankizumab was also superior to secukinumab and fumaric acid esters in terms of PASI 90 response rate. In an ongoing open-label extension study (LIMMitless), risankizumab was associated with durable and improved efficacy after switching from ustekinumab or adalimumab, as well as durable maintenance of efficacy through > 2.5 years of continuous exposure. Treatment with risankizumab improved health-related quality of life and was generally well tolerated, both in the short- and longer-term. In conclusion, risankizumab represents a useful new treatment option for patients with moderate to severe plaque psoriasis.

show abstract

“…[31] Of interest, the role of anti-TNF-α treatment in psoriasis and psoriatic arthritis is already well documented. [34] Conventional DMARDs in patients with HI and chronic in ammatory arthritis have already been used without signi cant side effects. In a single case report worsening of erythroderma and increased cutaneous infections were reported, with poor disease control even using MTX and a biologic agent in combination.…”

Section: Discussionmentioning

confidence: 99%

Juvenile Idiopathic Arthritis in Harlequin Ichthyosis, a Rare Combination or the Clinical Spectrum of the Disease? Report of a Child Treated With Etanercept and Review of the Literature 

Baldo

Brena

Carbogno

et al. 2020

Preprint

View full text Add to dashboard Cite

Background. Harlequin ichthyosis (HI) is the most severe phenotype of autosomal recessive congenital ichthyosis. Juvenile Idiopathic Arthritis (JIA) represents a heterogenous group of disorders all sharing the clinical manifestation of chronic arthritis. Association of HI and chronic arthritis has been reported in few cases. Case presentation. We report the case of a child HI who developed a severe form of chronic polyarthritis during the first years of life, treated with repeated multiple joint injections, methotrexate and etanercept with good response and any adverse events. Conclusion. The case reported, followed by a review of the literature, could suggest the possibility that the presence of this peculiar severe polyarthritis with early onset and FR / ANA negativity, could be part of the clinical manifestation of Harlequin Ichthyosis instead that a rare combination of two diseases as reported by previous papers.

show abstract

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update

Cited by 138 publications

References 4 publications

Is chemoprophylaxis necessary for all latent tuberculosis infection patients receivingIL‐17 inhibitors? A cohort study

Is chemoprophylaxis necessary for all latent tuberculosis infection patients receivingIL‐17 inhibitors? A cohort study

Risankizumab: A Review in Moderate to Severe Plaque Psoriasis

Juvenile Idiopathic Arthritis in Harlequin Ichthyosis, a Rare Combination or the Clinical Spectrum of the Disease? Report of a Child Treated With Etanercept and Review of the Literature

Contact Info

Product

Resources

About

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update

Cited by 138 publications

References 4 publications

Is chemoprophylaxis necessary for all latent tuberculosis infection patients receivingIL‐17 inhibitors? A cohort study

Is chemoprophylaxis necessary for all latent tuberculosis infection patients receivingIL‐17 inhibitors? A cohort study

Risankizumab: A Review in Moderate to Severe Plaque Psoriasis

Juvenile Idiopathic Arthritis in Harlequin Ichthyosis, a Rare Combination or the Clinical Spectrum of the Disease? Report of a Child Treated With Etanercept and Review of the Literature&nbsp;

Contact Info

Product

Resources

About

Juvenile Idiopathic Arthritis in Harlequin Ichthyosis, a Rare Combination or the Clinical Spectrum of the Disease? Report of a Child Treated With Etanercept and Review of the Literature